Tributyrin — The Bioavailable Butyrate Prodrug

Tributyrin is a triglyceride containing three butyrate molecules, acting as a prodrug that bypasses the pharmacokinetic limitations of free butyrate. Upon ingestion, it is hydrolyzed by lipases in the gastrointestinal tract, releasing butyrate directly into the colon and systemic circulation. Butyrate functions as a histone deacetylase (HDAC) inhibitor, promoting epigenetic modifications that enhance gene expression related to cellular defense and longevity. It also serves as a primary energy source for colonocytes, maintains gut barrier integrity, and exerts potent anti-inflammatory effects by suppressing NF-κB signaling.

Human trials of tributyrin are limited but expanding. Early Phase I oncology trials established its safety and pharmacokinetics at high doses. More recent pilot studies and clinical trials are investigating its effects on the gut microbiome, Parkinson's disease, and cognitive impairment, demonstrating its ability to increase systemic butyrate levels and modulate microbial communities.

150–300 mg/day is the standard range for commercial supplements (often as CoreBiome®), while clinical trials in oncology have used much higher doses (up to 150–400 mg/kg/day). Typically taken orally in capsule form.

Generally well-tolerated at standard supplement doses. High doses used in clinical trials (e.g., >150 mg/kg) may cause gastrointestinal distress, nausea, or headache. Long-term safety data in healthy populations for longevity purposes is currently lacking.

Key Papers